Stock Research: Bristol-Myers Squibb

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Bristol-Myers Squibb

NYQ:BMY US1101221083
44
  • Value
    80
  • Growth
    51
  • Safety
    Safety
    21
  • Combined
    44
  • Sentiment
    39
  • 360° View
    360° View
    44
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases. It operates in oncology, hematology, immunology, and neuroscience. The company operates globally. In the last fiscal year, the company had a market cap of $94,489 million, profits of $36,351 million, revenue of $48,300 million, and 34,100 employees.

more
Index
D.J. US Health Care
D.J. US Pharmaceutical
S&P 500
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
80 92 92 97
Growth
51 43 7 27
Safety
Safety
21 30 31 35
Sentiment
39 40 68 51
360° View
360° View
44 51 39 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
5 9 10 34
Opinions Change
4 12 48 64
Pro Holdings
n/a 88 87 40
Market Pulse
80 79 78 68
Sentiment
39 40 68 51
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
80 92 92 97
Growth
51 43 7 27
Safety Safety
21 30 31 35
Combined
44 58 29 52
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
70 43 37 40
Price vs. Earnings (P/E)
62 83 91 96
Price vs. Book (P/B)
31 23 19 35
Dividend Yield
97 98 98 98
Value
80 92 92 97
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
17 6 25 11
Profit Growth
98 100 31 47
Capital Growth
36 17 26 48
Stock Returns
31 61 37 73
Growth
51 43 7 27
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
19 16 24 34
Refinancing
14 27 25 25
Liquidity
73 75 76 66
Safety Safety
21 30 31 35

Similar Stocks

Discover high‑ranked alternatives to Bristol-Myers Squibb and broaden your portfolio horizons.

Micron

NSQ:MU
Country: USA
Industry: Semiconductors
Size: XX-Large
Full Stock Analysis

Cognizant Technology

NSQ:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

Salesforce

NYQ:CRM
Country: USA
Industry: Application Software
Size: XX-Large
Full Stock Analysis

Walt Disney

NYQ:DIS
Country: USA
Industry: Movies & Entertainment
Size: XX-Large
Full Stock Analysis

Frequently Asked
Questions

The only strength is good value. All other factors (growth, safety, and sentiment) are below average. This stock is highly sensitive to a crisis and is not advisable. Avoid unless you have solid, independent reasons to believe a significant turnaround is imminent.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: